<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A female newborn infant with Marfan-like habitus experienced <z:hpo ids='HP_0001254'>lethargy</z:hpo> and <z:hpo ids='HP_0002045'>hypothermia</z:hpo> associated with <z:hpo ids='HP_0003231'>tyrosinemia</z:hpo> that was not corrected by the administration of <z:chebi fb="6" ids="22652,29073">ascorbic acid</z:chebi> at 50 mg/day but that subsequently responded to <z:chebi fb="6" ids="22652,29073">ascorbic acid</z:chebi> at 500 mg/day </plain></SENT>
<SENT sid="1" pm="."><plain>Cerebrospinal fluid analysis for neurotransmitter metabolites showed elevated concentrations of homovanillic acid and 5-hydroxyindoleacetic acid when the child was symptomatic and <z:mpath ids='MPATH_458'>normal</z:mpath> concentrations after successful ascrobic acid therapy </plain></SENT>
<SENT sid="2" pm="."><plain>These observations suggest that a high level of tyrosine in serum can affect the metabolism in the brain of <z:chebi fb="40" ids="18243">dopamine</z:chebi> and <z:chebi fb="19" ids="28790">serotonin</z:chebi> </plain></SENT>
</text></document>